Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q2 2024 · 10-Q
Revenue$0.00$0.00−100.0% vs Q2 2023 Net Income-$38.84M-$38.84MN/M vs Q2 2023 EPS Diluted$0.59$0.59−98.5% vs Q2 2023 Operating Income-$44,147,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
derived
ended Jun 30, 2024 · filed Aug 7, 2024 · 38 d after period end